Hepatitis C News and Research

Latest Hepatitis C News and Research

Home-based health education about diseases most effective, finds study

In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Gold nanoparticles are tiny spherical particles made out of gold atoms with sizes on nanometre scale. This is around 1,000 times smaller than the thickness of human hair.

23 Apr 2013

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Vertex Pharmaceuticals Incorporated today announced data from a Phase 2 study of VX-661 and ivacaftor that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, known as F508del.

22 Apr 2013

Researchers decipher the underlying mechanism of antiviral drug

A long-forgotten candidate for antiviral therapy is undergoing a renaissance: Since the 1970s, the small molecule CMA has been considered a potent agent against viral infections, yet it was never approved for clinical use.

22 Apr 2013

Indian drug supplier cuts price of 5-in-1 childhood vaccine for GAVI Alliance; Groups highlight World Immunization Week

"The cost of immunizing children in developing countries with a five-in-one vaccine is set to fall after a deal by an Indian supplier to slash the price it charges the GAVI global vaccines group," Reuters reports.

19 Apr 2013

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

Inovio Pharmaceuticals, Inc. announced today that its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain.

19 Apr 2013

Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

National Institutes of Health scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells.

19 Apr 2013

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

RNAi-based therapeutics company Benitec Biopharma Limited today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee.

18 Apr 2013

Flunisyn Phase 2a trial data shows positive results in elderly population

Following the widely publicised US Centers for Disease Control and Prevention report in February that the current season's flu vaccine is only 9% effective in the over-65 population, Immune Targeting Systems Limited, today announces positive data from a Phase 2a trial with the Company's lead pan-strain influenza A T-cell vaccine, Flunisyn, in the elderly population.

17 Apr 2013

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections.

16 Apr 2013

Study reveals inner workings of master regulator that controls diverse functions

New discoveries by a team of scientists at LSU Health Sciences Center New Orleans for the first time reveal the inner workings of a master regulator that controls functions as diverse as the ability of nerve cells to "rewire" themselves in response to external stimuli and the mechanism by which certain viruses hijack normal cellular processes to facilitate their replication that can ultimately lead to cancer. The research will be published in the April 12, 2013 issue of the Journal of Biological Chemistry.

12 Apr 2013

New approaches to treat persistent viral infections like HIV and hepatitis C

UCLA scientists have shown that temporarily blocking a protein critical to immune response actually helps the body clear itself of chronic infection. Published in the April 12 edition of Science, the finding suggests new approaches to treating persistent viral infections like HIV and hepatitis C.

12 Apr 2013

New research shows safety can be improved for people participating in medical experiments

In almost 90 per cent of cases, novel drugs tested on humans by pharmaceutical companies do not work as intended and must be scrapped. Often the drugs do not work, while at worst, test subjects die. New research from the University of Southern Denmark now shows that this number can be reduced.

12 Apr 2013

MKK4 gene could be a promising therapeutic target for liver disease, study reveals

Chronic liver failure is a major health problem that causes about one million deaths around the world each year. A study published April 11th by Cell Press in the journal Cell reveals a new type of screen for identifying genes that promote liver repair in mouse models of both acute and chronic liver disease.

12 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Nev. jury orders HMO to pay $500M in punitive damages after hepatitis C outbreak

A Nevada jury has awarded three plaintiffs $500 million in punitive damages after finding negligence.

11 Apr 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Home-based health education about diseases most effective, finds study

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Researchers decipher the underlying mechanism of antiviral drug

Indian drug supplier cuts price of 5-in-1 childhood vaccine for GAVI Alliance; Groups highlight World Immunization Week

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Flunisyn Phase 2a trial data shows positive results in elderly population

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Study reveals inner workings of master regulator that controls diverse functions

New approaches to treat persistent viral infections like HIV and hepatitis C

New research shows safety can be improved for people participating in medical experiments

MKK4 gene could be a promising therapeutic target for liver disease, study reveals

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Nev. jury orders HMO to pay $500M in punitive damages after hepatitis C outbreak

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in